source
- Analysts spot several biotech firms as likely M&A targets amid rising pharma deal activityPharma companies are actively looking for acquisition opportunities, and analysts have identified a handful of biotech firms that could be next in line for buyouts. Recent transactions have center…
- BioNTech trims full-year COVID-19 vaccine sales outlook by up to 20% amid weak demandBioNTech announced it is lowering its full-year sales guidance for its COVID-19 vaccine. The company cut the midpoint of its outlook by almost 20%, moving the range to €1.6-1.9 billion from the pr…